Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The current status of PI3K inhibitors in hematological malignancies and challenges to overcome

Geoffrey Shouse • 12 Dec 2022
ASH 2022
General Umbralisib

Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, briefly discusses the current status of PI3K inhibitors in the treatment of hematological malignancies, and further highlights the need to develop less toxic combinations with these agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.

More from Geoffrey Shouse

0:43
The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL
Geoffrey Shouse • 11 Dec 2023
0:58
Novel approaches in Richter's transformation: CAR-T and bispecifics
Geoffrey Shouse • 11 Dec 2023
0:51
Phase I study of copanlisib plus venetoclax in R/R DLBCL
Geoffrey Shouse • 11 Dec 2023
0:58
First-in-human trial of CLN-978, a novel CD19 bispecific antibody, for the treatment of R/R B-NHL
Geoffrey Shouse • 11 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals